The Series Podcast Objectives are:
Podcast objectives include understanding how the medical affairs strategic planning process can drive decision making throughout the year
• Develop leadership and motivational skills that will help Medical Affairs colleagues build cross-functional relationships and engagement, in order to successfully deliver integrated medical activities
• Awareness that effective collaboration requires modifying interpersonal interactions to account for different functions/nationalities having different backgrounds/cultures/ways of working/motivations
• Recognition that a major cause of disharmony/disengagement/demotivation is an individual feeling threatened in some way, and the implications of triggering a ‘threat’ response
• Knowledge of the SCARF model (NeuroLeadership Institute), its key components {Status, Certainty, Autonomy, Relatedness, Fairness} and their importance in triggering a ‘reward’ response
• Understanding of how the SCARF model can be applied by Medical Affairs colleagues in their everyday roles and interactions with colleagues
Access Options
https://medicalaffairs.org/wp-content/uploads/2020/09/SCARF-Model-Featured.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-10-29 14:06:062024-03-14 13:59:17How to succeed in cross-functional collaboration: the SCARF model for Medical Affairs
This Medical Affairs Professional Society (MAPS) podcast features medical affairs thought leaders offering insights into the Medical Affairs strategic planning process
https://medicalaffairs.org/wp-content/uploads/2020/10/MedStrat-1-Featured.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-10-19 06:31:452023-11-13 10:07:05PODCAST: Medical Affairs Plans — From Strategic Planning to Measuring Impact
Murali Gopal, MD, Vice President | Global Medical Department at Mallinckrodt
Murali Gopal, MD, remembers being a young clinician in the bygone era of giveaways during conference meetings when he would walk by pharma booths and pick up a water bottle or a tie or whatever they may be giving away. Would he ever wear the tie or use the water bottle? Probably not. But it cost him nothing and so why not? Now Murali compares this might-as-well approach to the biopharmaceutical industry’s traditional (and increasingly outdated) model of brand planning. As Vice President of the Global Medical Department at Mallinckrodt Pharmaceuticals, he is helping his organization evolve into a future that includes the contributions of science and business to attain the goal of innovation. Here the Medical Affairs Professional Society (MAPS) talks with Murali about the strategy he uses to guide this change – Integrated Brand Planning – which he not only credits with bridging the gap between science and business in biopharmaceutical organizations, but sees as a philosophy that has led to his personal development as a leader and decision-maker.
MAPS: Okay, you have to start by telling us how brand planning is like stocking up on conference giveaways.
Murali: Think about what happens when Medical Affairs comes over and says we can generate X, Y and Z data for an asset – if you’re a Commercial person and you’re trying to maximize the opportunity of the molecule, and have no financial downside or obligation…why wouldn’t you take all options? It’s the same mentality as conference swag: If you can get something for nothing, you do it. That may have worked well without today’s challenges. But now companies that still use this model place themselves at a disadvantage.
MAPS: You’re saying this model of saying yes to all possibilities for a new drug leads to inefficiencies?
Murali: Yes, I am saying that, and that it also leads to increased costs and the need for increased resources. At a previous position, we ended up with 7,000 different promotional materials for one molecule in one year. Some were used once and some just sat in warehouses. A handful of them would be the key materials that were used over and over. It was as if we were creating things for the sake of creating things and not focusing on what the external stakeholder may have felt was most compelling or intriguing. Another example can be that perhaps the organization may determine they need some data without fully understanding that it may take five years to conclude a particular study, or may cost, say, $3 million dollars.
MAPS: And how is Integrated Brand Planning different?
Murali: With Integrated Brand Planning, or what some organizations call the General Manager model, the GM becomes responsible for the profit and loss of a molecule. What this means is that everything becomes visible. Commercial, safety, R&D all becomes visible, because they’re all centered around some level of cost. It forces the organization to align on their priorities and to create targeted strategies.
MAPS: It sounds like you’re talking about a more integrated flow of information between science and business during brand planning?
Murali: Traditionally the separation between science and business was intentional. Many scientists felt, and some may still feel, that science and business need to be separated and if Medical Affairs or Commercial has input to science, it takes away some of the scientific credibility. I like business but I’m a scientist at heart – I want to be measured against the science we engage in, and fortunately the GM model allows us to do both so that I can continue to grow my business acumen as well.
MAPS: What do you mean?
Murali: Let’s say our end goal is innovation – we live longer today because innovation helped us learn to deal with illnesses that would have killed us in our 30s and 40s. And look at the effect of the cholesterol medicine race in the cardiovascular space, heart transplants, etc. or the vaccine industry in general. The biopharmaceutical industry has always struggled to articulate the impact of innovation on society. But combining the business impact and scientific development aspects together, we can now measure and even predict how a therapy is going to provide value, as well as, to understand its economic impact so that we can make better decisions.
MAPS: You’re saying business has a role in innovation?
Murali: Certainly. At a previous position, we hired a top scientist in their field to work with a new molecule. He had great relationships, knew the unmet need, knew what the molecule could do, but he didn’t take into account what other companies were doing, or the needs of payor organizations, or the high level of focus on pricing at that time. When we got ready to introduce the molecule, the potential price and utilization scared the payors – they said it was going to break the healthcare system and that we would need to somehow restrict who is eligible for the therapy, and if we couldn’t do that, possibly no one would get it. Our internal leader couldn’t accept these business realities and the drug was by many measures unsuccessfully launched. For me, that was a very poignant experience. The fact is, you need relationships with scientific leaders, but to run a therapeutic area, you need just as much acumen on the landscape and business side to marry with the scientific aspects to be successful.
MAPS: This sounds like a cautionary tale of science overbalancing business, but of course we have cautionary tales in which business overbalances science as well.
Murali: I believe there are companies out there increasing profitability and cost because they can, but there are also companies trying to do the right thing, and it all gets lumped together. Integrated Brand Planning creates checks and balances.
MAPS: Oh, interesting! And how is that?
Murali: It’s about collaboration at the stage of annual planning. Instead of Commercial proposing studies to R&D, or R&D proposing studies to Commercial, with Integrated Brand Planning, it’s a collaborative, open discussion from the start. Scientists don’t need to also be MBAs and Commercial doesn’t need to hold PhDs, but the dialogue helps scientists elevate their business acumen, and Commercial elevate their scientific acumen. You need the perspective of external stakeholders as well. Most companies will put the patient or a disease at the center of what they do, then you have your organization or company’s resources sitting in the next circle around this center, but there’s an external circle as well that includes: advocacy groups for that therapeutic area, politicians, KOLs in academia, clinicians, etc. This brings the awareness and impact of patient journey and access journey into the planning process.
MAPS: It sounds challenging to help organizations transition from the traditional, siloed way of doing things into this new model of collaboration. What do you do to help generate this?
Murali: Three things. First, I’m trying to educate the scientific organization this can work and not to be afraid, but rather to embrace it. Second, I’m trying to explain what good actually looks like by walking through my own process of evolution from previous experiences at other companies – maybe by seeing how it’s worked elsewhere, we can skip some of the painful learnings. Third, I try to lead by example by sitting in wherever I can as a leader for the Medical organization.
MAPS: With collaboration comes complexity…
Murali: These actions have helped me develop not just as a better leader, but as a better individual. Balancing business and science in this collaborative process of brand planning helps me to not look at things as only black and white. It affects how I approach complex challenges. Sometimes in a discussion, you find out how complex something is and it surprises you through all of the aspects that may need to be considered and planned for. That’s fun for me. How we work together to solve complex problems is fundamentally interesting to me. And when you’re constantly looking at all these variables to make decisions, you get better at it, not just with regard to business decisions, but life decisions as well. When there are things that are hard to pick between, you can use the same mentality to make a well-rounded decision. It might sound strange, but after engaging and leading in this process for so many years, I feel like I ruminate on decisions a lot less, and that I am more secure in my decision-making ability. Don’t get me wrong, it takes effort. You can go through the motions and not get anything out of it. But I dug into it. I really wanted to unpack how far we could take commercial and scientific collaboration and I think it’s facilitated my growth as a leader and attaining this level in my career and in my life.
https://medicalaffairs.org/wp-content/uploads/2020/10/Murali-Gopal-Featured.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-10-15 12:05:062023-11-13 10:08:04Why Good Science is Good Business: A Conversation with Murali Gopal, MD
It’s no secret that major forces have pushed the pharmaceutical industry to think differently about how it operates and how it can deliver greater value to society. The good news is that we’re seeing more connected, more agile and more outcomes-focused organizations arise from the disruption.
R&D teams have increasingly broken free from traditional scientific silos through increased internal collaboration and external partnerships with biotech and academia. They have embraced transformative science and technological advances and we are starting to see a new generation of medicines forged by our enhanced ability to capture, interpret and apply data.
Our engagement models have also adapted to changing stakeholder needs. More specialty products with more complex data mean that our clinical and access stakeholders are demanding deeper scientific exchanges to understand the patient impact and value to society.
What’s changed in Medical Affairs?
Like many pharma companies, the role of Medical Affairs at Astellas has transformed in recent years, from a support function to a strategic organization to internal and external stakeholders.
Today, Medical Affairs is comprised of the most important and valued capabilities in the business, playing the role of key connector between internal pharma and external stakeholders.
We are driving scientific exchange and evidence generation with an ever-expanding external stakeholder community of healthcare professionals, scientific experts, health authority bodies, payers and patients.
Our role is not just limited to knowing what these stakeholders want and need. We’re fulfilling information needs through data-generation (clinical trials and real-world data analyses), data sharing through publications, medical information and scientific exchange, pinpointing the investments and activities that will drive the biggest impact for each of these groups. The result, ensuring the safety, efficacy, value and real-world utilization of our therapies are fully understood.
As Medical Affairs integrates its wealth of external insights into a consolidated and aligned strategy to guide its own global activities, it also needs to align with Commercial and R&D colleagues. Through governance and operational excellence, Medical Affairs ensures information needs and data are shared across organizations, as and when needed, to enhance the effectiveness and impact of all respective groups.
Leading value creation in the future
As our operating environment has changed, Medical Affairs has become a more business-savvy, scientifically influential, connected and agile function. While we’re making great progress, companies like Astellas know that the disruption won’t stop.
New challenges lie ahead, such as our ability to address wider societal issues and to create value for a variety of stakeholders that is wider than ever before. Another key challenge for us will be the use of artificial intelligence to generate data from combined big data sources, such as clinical health records, real-world data and the variety of ‘omics’ data sets. This information will need to be delivered in an increasingly digitally-savvy way, for example via interactive medical information websites and other digital channels.
We also know that downward pricing pressures are unlikely to go away. We will need to demonstrate how innovations create value to a wider variety of stakeholders than ever before. So, every commercial decision will have greater consequences.
With this mind, I believe that Medical Affairs professionals must continue to build on the range of capabilities that enable them to act as orchestrators of company strategy with R&D and Commercial functions. Central to this is effective leadership. Medical Affairs leaders need to be ready to interact with the C-Suite and inform corporate strategies because it is helping companies to make smarter decisions and focus performance measures on patient-centric outcomes. And that’s value creation that makes a real difference.
https://medicalaffairs.org/wp-content/uploads/2020/10/Charlotte-Op-Ed-Featured.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-10-13 10:31:462023-11-13 10:08:13MAPS Board Chair, Charlotte Kremer: Why The Strategic Rise of Medical Affairs Is Central to Pharma’s Future Success
Joseph Eid, MD, SVP, Head of Global Medical Affairs at Bristol Myers Squibb, describes how Medical Affairs can ensure representation of the patient voice in product development, and the positive shift and elevated prominence Medical Affairs is achieving within companies.
If the video above does not play, or to view full screen, CLICK HERE to open in a new window.
Download the Presentation
Members may also download a PDF copy of Dr. Eid’s panel discussion on The Value of Medical Affairs from the MAPS 2020 Global Annual Meeting as well as a recording of the session in the Community Portal.
View the White Paper
You may also view our latest white paper on the Communicating the Value of Medical Affairs, by clicking here.
https://medicalaffairs.org/wp-content/uploads/2020/06/Joseph.Eid_.Interview.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-06-10 20:56:342023-11-13 10:19:37Interview: The Value of Medical Affairs
Executive stress has come under scrutiny recently, most pointedly in an open letter published by Arianna Huffington, founder of the Huffington Post, to Elon Musk, in which she appealed to him to change the way he works to be more in line with the science of how humans are most effective.
The letter came hot on the heels of the Tesla chairman and chief executive’s anguished New York Times interview where he broke down multiple times as he recounted the excruciating pressure he was under in what he named “the most difficult and painful year of my career”. Asked if the exhaustion was taking a toll on his physical health, Musk answered: “It’s not been great, actually. I’ve had friends come by who are really concerned.” The public admission subsequently sparked a tumble in Tesla shares.
Huffington decried Musk’s 120-hour weeks and continued with an argument calculated to break through his denial – science. Musk is nothing if not a scientist, so Huffington asked him to look at the science of human overwork and sleep deprivation: “The science is clear. And what it tells us is that there’s simply no way you can make good decisions and achieve your world-changing ambitions while running on empty.”
“To cite just one study, after 17-19 hours without sleep, we begin to experience levels of cognitive impairment equivalent to a blood alcohol level of 0.05%, just under the threshold for being legally drunk. No business leader would hire people who came to work drunk, so don’t model that behavior for your employees.”
The missive drew a Twitter response from Musk. “You think this is an option. It is not.” Huffington, founder of wellness website Thrive Global, where she published the open letter, refuses to accept that. In fact, she sees a lesson here for us all. “This is not about sleep, or about slowing down, or about asking Elon to chill out under a mango tree,” she said in a statement shared with CNN. “It’s about how we can unlock and sustain our peak performance, and see solutions and opportunities where others can’t.”
The running debate highlights some key points. “Firstly, people who are burnt out are the last to see it and it takes others, family members or friends to point it out to them,” says Lewis Garrad, Business Lead for Employee Experience Research at global consulting firm, Mercer. “Secondly, there’s the question of whether it’s an employer’s responsibility or that of the individual.”
Huffington would argue that burning out is not the price of success. “As all the recent scientific findings show, the opposite is true,” she said, noting people “perform better” when they “take time to refuel and recharge.”
Picking up the pieces
According to Jenn Fenwick, Founder of Rebel Road Executive Coaching, who frequently coaches stressed-out executives, it comes down to sustainability. “There’s a balance between the duty of care of the employer to support the employee and the responsibility of the individual to manage their own health and wellbeing. Frankly, in my experience, leaders are frequently left out at sea, especially during extremely stress-inducing times like transitioning into more senior positions. The employer is often not forthcoming in terms of providing onboarding support, and employees are left floundering – not sleeping, experiencing severe anxiety due to lack of internal support, lack of clarity around the role, and this ‘all-or-nothing’ approach where the employee forsakes all health and wellbeing activities in order to prove to their employers that they made the right decision in hiring them.”
It’s a considerable cost to the employer. “Many often leave because of burnout. In this one case, it was going to lead to losses of £200,000 if this particular senior Medical leader resigned – not to mention the impact on team morale if she left. As a coach, I’ve had a lot of experience of rescuing situations where leaders are on the point of leaving due to overwhelm. Employers need to provide better support particularly at flashpoints like transitioning to new roles, or during mergers and takeovers where people can suffer due to lack of communication from the top and insecurity surrounding the continuity of their role. But employees also need to learn how to self-care,” says Fenwick.
A tailored approach
While well-managed wellness programs are beneficial in redressing the onset of workplace stress and burnout, they often target the wrong cohort. “You’ll often see the highest uptake in these wellness programs are among those that least need them – the people who are typically health-conscious anyway and are into health and fitness. The likely burnout candidates may not take up these initiatives and this is where we need to have a more personalized approach to the issue of burnout. Are there other stressors at play within the overall culture? Are there other stressors at play, which are impacting on employees’ stress levels, like financial concerns? Tailored programs – for example, financial security programs – may be appropriate in this instance so it’s vital to acknowledge that one-size does not fit all. We need a very tailored approach to the issue,” says Garrad.
Christina Maslach, creator of the Maslach Burnout Inventory and author of The Truth About Burnout, has identified six “mismatches” that make a person more likely to burn out – and only one of these factors is too much work. “It is a common belief that there is just one dimension to job stress, work overload. Indeed, overload is often considered to be a synonym for stress. But in our burnout model, overload is only one of six mismatches in the workplace. And it’s not always the most critical, especially it things are going well in some of the other areas.” (2) Maslach cites five other triggers than can lead to burnout, including lack of control, insufficient reward, lack of community, absence of fairness, and conflict in values.
Mental health strain
The health and safety precautions applied to an employee’s physical health apply equally to their mental health. Jeffrey Pfeffer is professor of organizational behavior at Stanford University Graduate School of Business. In his most recent book, Dying for a Paycheck, he writes:
“The workplace profoundly affects human health and mortality, and too many workplaces are harmful to people’s health – people are literally dying for a paycheck.”
Pfeffer cites extensive examples from across the globe of the negative effects toxic work practices have had on people – to the point, in some cases, of pushing them to suicide. Other examples given include serious health effects such as collapsing from fatigue, developing a dependency on anti-depressants, or substance abuse. (3)
“For men, prolonged exposure to work-related stress has been linked to an increased likelihood of lung, colon, rectal, and stomach cancer and non-Hodgkin lymphoma. Moreover, we are increasingly understanding the mechanisms linking stress to disease.”
Pfeffer namechecks a few positive cases throughout the book. He cites companies such as Southwest Airlines, Toyota, and SAS Institute for their resistance to layoffs, and Patagonia and Aetna for progressive policies regarding healthcare insurance and work-life balance.
His response to corporate wellness programs as a salve to reduce burnout is that they are largely ineffectual, mainly because they focus on the wrong things. “We know, from extensive research summarized in Dying for a Paycheck that individual behaviors such as overeating, smoking, excessive alcohol consumption, and drug abuse are related to the stress, including workplace-induced stress, that individuals experience. So instead of trying to get people to engage in healthier individual behaviors, workplace wellbeing initiatives would be more effective if they focused on preventing the stress-inducing aspects of work environments that cause the unhealthy individual behaviors in the first place. Simply put, companies need to build cultures of health – and that begins by creating work environments that help people thrive both physically and psychologically. Not on trying to remediate the harm that toxic workplaces inflict through limited-intervention ‘programs’.” (4)
The solution is simply the flip side of his data: it’s providing more job control, reducing work-family conflict, being fair to employees and providing social support at work. It’s also avoiding lay-offs; Pfeffer quotes evidence that while layoffs “increase fear and stress, they do not lead to higher profits, productivity, stock price, innovation or quality.”
Creating safe, supportive human environments
For Danie du Plessis, it’s time to bring workplace stress out into the open. The Executive Vice President of Medical Affairs at Kyowa Kirin, du Plessis has a strong background in coaching and mentoring, with a heavy emphasis on employee health and wellbeing.
He explains: “In the UK, there has recently been a huge emphasis on mental well-being in the workplace, including support from the House of Windsor. This is great and can unfortunately also have a downside of not seeing the bigger picture and how many factors influence an individual’s resilience. Both individuals and employers have responsibilities. Employees need to take time to understand their own purpose in life, in the first instance, and how that relates to the work they are doing and their career aspirations (a great coaching/mentoring conversation). They need to be aware how they manage problems, emotions and their own physical well-being, and be prepared to change their own behavior if the status quo does not serve them well. This will increase their resilience and fulfillment. It is quite amazing how often resilience becomes a key conversation in coaching and mentoring. Sadly, many people are scared to be open at work and discuss this with their managers.”
According to du Plessis, employers need to create a safe space for employees to be themselves at work and be vocal about the fact that it is OK to be human. “Offering access to different programs that inform the journey of growth towards managed resilience is the ideal – either in-house or through third parties. I believe this should be the norm for all companies and organizations, while one should appreciate that different size companies will have different offerings. What is in it for the company? Resilient employees perform better and retain their aligned passion for the purpose of the company, which is why they joined in the first place. It becomes easier to really be present (which links again with mindfulness and mental well-being). This takes the term ‘presenteeism’, coined by Professor Cary Cooper, a psychologist specializing in organizational management at Manchester University in the UK one step further. And by default, absenteeism decreases which reduces workload on co-workers. Having a reputation of caring about employees can in no perceivable way harm any organization.”
Psychologically safe versus fearing the next round of layoffs
Prioritizing your employees over the short-term goals of your company can be the best strategy in the long run, according to Simon Sinek, author of Leaders Eat Last.
“The irony is when our top priority is to take care of our people, our people will take care of the numbers. People-focused companies outperform numbers-focused companies over the long-term dramatically.”
When organizations take care of their employees to such an extent, they make them feel safe. And according to Simon Sinek, the natural response to feeling safe is to offer trust and cooperation.
“Charlie Kim, who is the CEO of a company called Next Jump, a tech company in New York City, makes the point that if you had hard times in your family, would you ever consider laying off one of your children? We would never do it. Then why do we consider laying off people within our organizations? Charlie implemented a policy of lifetime employment. If you get a job at Next Jump, you cannot get fired for performance issues. In fact, if you have issues, they will coach you and they will give you support, just like you would if one of your children came home with a C from school.”
Ben Whitter, Founder and CEO of World Employee Experience Institute, suggests that both employees and employers have a role in creating the conditions for burnout to occur. “The thing about some companies, and the tenure figures from Silicon Valley bear this one out, is that they can create a fantastic workplace experience, but in return, they expect EVERYTHING an employee’s got to give, which is very intense and challenging to sustain over the long-term. The increasing numbers of people opting to work freelance within the gig economy is an indicator that people want to take back control of their life and work to hours that suit them. Companies are responding with various flexible working arrangements, and also the four-day week is growing in popularity, to deliver stronger productivity that can be sustained by the employer and employees. Work and life are converging at a rate we haven’t seen before, and everyone needs to get ready for radically new ways of working within the economy.
Employees are no longer resources to be exploited and commanded, they are now allies in a shared mission to co-create experiences that deliver better results. For Whitter, the future of work and HR is human and this human touch is where we need to get to. “A quote I love from Trudy Purchase (an Employee Experience Award Winning Learning & Development Manager) is: ‘“Don’t judge the quality of an employer by how they treat you on your best day. Instead, judge them by how they treat you on your worst day.’ And in return for that humanity you get a whole lot more: discretionary effort, loyalty, creativity, innovation, because if you treat me like this, I’ll give you everything I have. It certainly beats free snacks or fußball tables.”
https://medicalaffairs.org/wp-content/uploads/2020/08/9-1.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-03-07 01:59:492023-11-13 10:25:59The Human Touch: The Real Issues Behind Burnout
MA has seen an exponential growth over the last decade as it value and place within the pharmaceutical industry is being realised. The evolution of MA from a support function to strategic partner has changed the direction of MA and also required an evolution of skill sets for the roles which underpin MA.
As a profession, there is still a void with a globally recognised advanced scientific qualification, capability frameworks across the main 3 role types and accreditation.
This collaborative webinar aims to discuss available postgraduate courses and insights from alumni into how their qualification helped advance their understanding of pharmaceutical medicine and their career.
• Understand what educational opportunities are open to MA professionals and also those aspiring to enter the profession
• Comprehend the content of programmes and how it relates to roles
• Discuss the future of MA in terms of universal recognition of a base qualification which can then be regionally adapted
Access Options
https://medicalaffairs.org/wp-content/uploads/2020/07/Professional-Education-OD-Featured.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2020-03-03 23:47:592024-03-06 11:20:41Professional Education, Capabilities and Identity in Medical Affairs
Dubbed by New York Times best-selling author and leadership guru Tasha Eurich as the meta-skill of the 21st century, self-awareness is as desirable as it is elusive, given that a staggering 95 per cent of people think they possess self-awareness, but only about 15 per cent of people really do. Self-aware people are more fulfilled, more creative, successful, more confident, build better relationships, and are more respected and effective leaders with more profitable companies. There’s just one problem: most people don’t see themselves quite as clearly as they could, and it’s rare to get candid, objective feedback from colleagues, employees, and even friends and family.
In her new book, Insight, organizational psychologist Eurich tackles this paradox and offers an explanation for this disconnect. “The reason I call it the meta-skill is that it’s underlying or foundational to all of the skills that are required to succeed in the 21st century – things like emotional intelligence, influence, persuasion, sales. If you are not self-aware, if you do not understand who you are, how others see you and the role you play in the world, you are going to come up short. But for most people, it is easier to choose self-delusion over the cold hard truth.”
Eurich argues that the increasingly “me-focused” society makes it easier to fall into this trap. “Recent generations have grown up in a world obsessed with self-esteem, constantly being reminded of their special qualities, and it is fiendishly difficult to examine objectively who we are and how we’re seen.”
Indeed, psychological research indicates that are we are not very good at evaluating ourselves accurately, frequently overestimating our abilities: for example, the Dunning-Kruger effect results in “illusory superiority” – a condition of cognitive bias whereby a person overestimates their own qualities and abilities, in relation to the same qualities and abilities of others. What’s even more alarming is that those with the least ability are most likely to overrate their ability to the greatest extent.
Decoding self-awareness
For Anne Welsh, Executive Coach and founder of Synthesis-in-the-City, the first step for a leader is to have a willingness to be self-reflective and, from being self-reflective, to build greater self-awareness over time. “If we think about the old style of leadership, it was very different from now where leaders are asked to be a lot more relational. Personally, I think that it takes courage to build self-awareness, because if you become more self-aware in one area, if you like, you have to actually open to your shadow as well as the positive aspects of self-awareness. So, I think self-awareness is a leadership journey and it demands courage.”
For Welsh, this journey needs to be a conscious choice. “In some ways, this learning could come from feedback from others, from 360-degree feedback from subordinates, colleagues and supervisors, but also I think you can begin to choose to take ownership, even keeping a reflective journal, to begin to recognize what works well in my relationships with others and especially as a leader. Where do I, maybe, get caught where my own beliefs and mindsets are stopping me actually being able to be relational as a leader?”
3 Tips on Self-Awareness
Watch Tasha Eurich in the video below to learn how to become more self-aware by making three life adjustments: deciding to learn the truth, getting more feedback, and asking what you can do to make a change in every situation.
Internal and external self-awareness
In her book Insight, Eurich talks about two types of self-awareness: internal and external. “Internal self-awareness has to do with seeing yourself clearly. It’s an inward understanding of your values, passions, aspirations, ideal environment, patterns, reactions, and impact on others. People who are high in internal self-awareness tend to make choices that are consistent with who they really are, allowing them to lead happier and more satisfying lives. Those without it act in ways that are incompatible with their true success and happiness, like staying in an unfulfilling job or relationship because they don’t know what they want.”
External self-awareness according to Insight is about “understanding yourself from the outside in – that is, knowing how other people see you. Because externally self-aware people can accurately see themselves from others’ perspectives, they are able to build stronger and more trusting relationships. Those low in external self-awareness, on the other hand, are so disconnected with how they come across that they’re often blindsided by feedback from others.”
Eurich names “three building blocks” that must be in place for a leader to drive a self-aware team.
“First, if the team doesn’t have a leader who models the way, the process will be seen as insincere or even dangerous. Second, if there isn’t the psychological safety to tell the truth, the chance of candid feedback is almost zero. But even with all this in place, you need an ongoing process— not unlike Ford CEO Mulally’s BPR (Business Plan Review) to ensure that the exchange of feedback is built into the team’s culture.”
For Welsh, it comes down to reviewing your emotional state and having the awareness and capacity to shift that state when needed. “Internally, consider what sort of state am I in: am I in a state that’s available and do I have the capacity to shift my state? And this is where mindfulness can come in or knowing how do we shift our state at any given moment.
The second self-awareness is about awareness of ourselves in relation to others and that takes quite a lot of sensory awareness as well. So, if we think that leaders maybe have to come from a place of ‘head, heart and gut’ (in the old leadership style, it’s much more head-identified) a leader can have greater sensory awareness and the guts to risk finding out ‘how am I coming across to others?’ So I think there’s a piece about awareness involving how we, as a self, are relating to others and how we’re impacting on the environment.”
Welsh advocates that leaders need to be conscious of their impact and how their message affects employees.” I think it’s picking up on body language, even if you think about a leader giving a presentation, do they talk at the people or are they gauging ‘how is this coming across to the people in the room? Are these people who need me to be more relational or do they just want slides?’ Because so often in presentations that leaders are giving, they’re just talking at the audience, they’re not checking out how this is landing, for instance asking “does this have a resonance with you?” which would be a much more relational way of interacting as a leader – so the leader actually asking questions, not just giving information.”
Welsh also advises that leaders be conscious of the dynamics at play within a team setting. “I love Nancy Kline’s work on Time To Think and if we look at self-awareness in teams, we have to be conscious of the psychological dynamics that go on within a team – noticing, what’s the role that I take on in any team; am I always the one that’s the challenger? Am I the icebreaker? Inviting teams to reflect on what are the dynamics that are going on in this team, alongside what is it that we have to do and what do we need to deliver? Because it might be that somebody gets labelled and gets scapegoated in a team and the other members of the team can feel quite comfortable because it’s not them. So, I think that in a team, helping them to think about what is the role that I maybe take on, even from [family] history – because teams are just like families: often you’ll find that the role that people took on in a family is the role that they’ll take on in a team. This can be useful, and especially it can be useful for the ones who are maybe playing a role that they actually don’t want to play anymore.”
Self-analysis trap
The quality of self-awareness requires self-reflection: the act of setting aside time – ideally every day – to quietly and honestly look at yourself, first as a person and then as a leader. Yet according to Eurich’s research, people who introspected were more stressed, more depressed, less satisfied with their jobs and relationships, less in control of their lives. She is in favor of a considered approach when it comes to self-reflection. “Self-analysis can trap us in a mental hell of our own making. Thinking about ourselves is not the same as knowing ourselves.”
Why questions: “why did I behave that way”, should be changed instead to “what”. “Why-questions trap us in that rearview mirror. What-questions move us forward to our future. As human beings, we are blessed with the ability to understand who we are, what we want to contribute, and the kind of life we want to lead. Remember, our self-awareness unicorns had nothing in common except a belief in the importance of self-awareness and a daily commitment to developing it. That means we can all be unicorns. The search for self-awareness never ever stops.”
Increase your self-awareness with one simple fix:
Finding and fixing blindspots
Blind spots can be the Achilles heel of leadership. Even the most iconic leaders have blind spots and, the more senior the leader, the less likelihood of receiving honest and accurate feedback from employees. Blind spots can help you maintain your confidence in the face of significant obstacles but, when they inhibit you from seeing the truth or make you blind to important issues, they need to be addressed. It’s not always easy to figure out what your own blind spots are and admitting them can seem like admitting weakness. Surround yourself with people who can help you manage your blind spots or weaknesses. If you don’t have strong analytical skills, recruit someone who can help you. If you tend to get defensive when your views are challenged, find a colleague or mentor who can help you deal with those feelings and process the information presented to you. By bolstering your team with people who help you overcome your blind spots, you’ll be better positioned to compensate for them.
https://medicalaffairs.org/wp-content/uploads/2020/08/14-1.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2019-05-20 19:35:052024-05-03 15:43:34Self-Awareness: How to deepen your insight and see the blind spots that could be holding you back
Can Medical professionals step up to a more strategic role? Dr. Ameet Nathwani discusses the need to define and measure our contribution, and why we must join together as a community to reshape the future of healthcare.
As technology advances inexorably transforming the healthcare landscape, Medical is poised for a more strategic role within pharma – that’s the view of former Chief Medical Officer of Sanofi, Ameet Nathwani. However, nobody with whom he works closely would be surprised to learn that he is not a fan of the term “Medical Affairs”.
“This harks back to an understanding of the way that Medical functions used to work about 15 or 20 years ago, which was much more around supporting the scientific base of the commercial organization. I prefer to just refer to the Medical function as it has evolved and expanded enormously; it’s a much more strategic function now and where it sits in Sanofi, reporting directly to CEO level speaks loudly to the progress made in this regard.”
New dynamics in the healthcare ecosystem
Underpinning this evolution are a series of distinct trends (see Figure 1) including the digital health revolution, the empowerment of the patient, and a requirement for continuous evidence generation. He explains: “It takes seven to eight years to develop a drug and, in that time, the healthcare system, the digital technologies, the innovation available, the way physicians practice, what the expectations of patients are, may have all fundamentally changed. So the question is: is the biologically innovative drug still relevant to patients and the healthcare system at the end of a long development process? And how do we ensure that digital health technology – the superconvergence of mobile, social, biometrics, genomics and AI – is being capitalized in everything we do? We see integrating digital health as a fundamental role of the Medical organization; from building a drugs-plus type of approach, through to real-world evidence is something the Medical function has to master.”
Taking control of RWE
Another driver of Medical’s current transformation is the requirement for continuous evidence generation. This is the melding of Real World Evidence (RWE), digital health, post-approval evidence and patient insight. “At Sanofi, Medical is in charge of the Real-World Evidence platform. We’ve built it and we, in turn, provide a service to R&D, Medical teams and Market and Patient Access. We should be able to move earlier into development, by leveraging the RWE platform for adaptive registration approaches to new products. With a really effective Real-World Evidence platform, good analytics and a transparent network, you could set up a very comprehensive, continuous observational program that continually helps to refine the benefits and risks of our products in real life as well as uncover new indications.”
Nathwani thinks how we maximize RWE will define the Medical function’s strategic value in the future. “We can’t be regarded as a strategic function if we’re not looking at how we can play a relevant role in the rapidly changing healthcare system. So, as a Medical function, we need to understand and define what the future of Medical should be in anticipation of these changes. How do we re-define ourselves? Where do we get our inspiration from – which other parts of the business or which other businesses do we send our medical teams to for inspiration? For example, are some of our Medical teams spending time at the Consumer Electronics Show, where you can pick up signals on future trends and behaviors of consumers in general – how a view of how these trends could be applied to the health sector? At Sanofi, we spend a lot of time engaging with tech companies to try and get a sense of where they are going and brainstorming on how to apply these to health. The main message is that Medical needs to look at what’s happening broadly in the world of technology, analytics, as well as in the traditional areas of medicine and healthcare, and zealously bring some of those ideas back internally to assess if we can integrate them to help us improve outcomes for patients.”
Measurement for Impact
One of the key challenges for Medical involves clarifying its new remit within the organization. Sanofi has selected nine strategic priorities for the function (see Figure 2), which serve as a roadmap for the transformation within the context of the evolving healthcare landscape. For Nathwani, the clarity this provides is a fundamental first step to making the function more value-driven, from early development right through to the end of the product lifecycle.
“There’s been a reluctance to measure the impact of Medical in the past as there wasn’t a clear definition of what it can achieve. We don’t measure return on investment, as commercial metrics don’t apply. We’ve been through this whole exercise of what we could do and what success looks like and how we measure the value that we bring: have we really made an impact on patients and physicians, have we fundamentally changed healthcare systems, have we introduced a drugs-plus solution that has truly improved outcomes? Do physicians regard the information provided by the Medical organization as credible, is the quality of the dialogue good, has it changed behavior? While complex and not easy to measure, these are the performance measures that we are trying to formulate in each pillar of our activities.”
Culture
Much of the work around redefining Medical’s role within the organization goes beyond just structural issues, and there are considerable challenges around culture and changing roles and expectations. “It’s probably the hardest thing to do right now. A first step is having top-down support. Following that, at the grassroots level, is there a clear roadmap or vision, is the platform that we’re trying to build and the vision for Medical truly understood by all stakeholders at all levels, including within the Medical function? There are many individuals in Medical today who have very different experiences and mindsets, some from a time where Medical occupied a more traditional support function role and maybe some of the teams are not fully convinced that we can truly make a difference to the strategic direction of the organization. It’s vital to get the whole organization on board and that comes from having a strong conviction, and a clearly defined roadmap of how to make this happen.”
A key component of a successful transformation will be an expansion of Medical’s capabilities – to allow a company to understand the patient experience, access, and influence a broad array of external healthcare stakeholders, and to act as a liaison between the medical community and the internal research organization.
“We described the required capabilities of the future Medical organization and we are creating the training platforms to accompany that. And we help them to understand the processes by which you transform. It’s not easy at the country level, where the ‘rubber hits the road’, because the pressure of the business and the resources and experience to lead change is much more difficult to obtain. We have taken the long view, so when we hire today, we try to hire for the future. We try to bring in people who have a better understanding of biotechnology, drug development, are strong on analytics and with a solid grounding in medicine, and where possible, a strong interest in the digital side. It’s tough. We also look for people with a very strong patient-centric focus as the energy and passion these individuals bring to our organization is tremendous, and keeps us grounded in our purpose”.
Together is better
With today’s life science industry now under extreme pressure to deliver superior medical outcomes while simultaneously cutting the cost of drug development, the time is right for Medical organizations to earn their place at the leadership table by creating opportunities to deliver new value for both patients and the healthcare ecosystem. Different companies are at different stages of maturity in terms of their progression towards being a fully-fledged strategic partner. However, the lack of a unified voice is hampering progress, Nathwani suggests.
“Our weakness is the heterogeneity of the role that Medical plays across organizations. We have extremes, from Medical as a well-accepted key strategic partner, right through to other organizations where Medical is probably more in the mainly customer support role. That heterogeneity means that it’s very hard to get alignment. If you look at the R&D organizations across industry, there is more clarity around their value and role. The main R&D leaders regularly meet together in a pre-competitive forum to look at the future direction of R&D and discuss macro trends. We don’t systematically do that across the Medical leaders in industry. There are a few useful platforms, but given the heterogeneity of our roles, the discussions are not consistent and our collective influence and voice is not at the level it could be.”
Nathwani is a strong advocate for Medical Affairs coming together as a community to decide on the future direction of MA. “We need to align on what are the key priorities that we believe Medical should be working towards across industry. For example, can we agree what would be a reasonable way to present the value of Medical internally and externally? Can we agree on what are the areas that Medical should try to drive within organizations – be that digital or drugs-plus or lifecycle management, and so on. Can we agree on the optimal methodologies for collecting and using RWE or utilizing advanced analytics for post-registration studies? What’s our approach on the many industry topics around bioethics?
“For example, in our organization, Medical runs the Sanofi Bioethics Committee, which helps to form company-wide positions on fundamental issues such as data transparency, the way we conduct trials, our approach to patient groups, positions on nanotechnologies or genetic therapies. Medical could be much more instrumental on matters like these if we had a platform across industry which could integrate positions from other companies and gain alignment on them. There’s a lot of areas I think that an organization like MAPS could focus on, to really elevate the Medical organization and its voice in our industry.”
Medical has a window of opportunity to become a strategic function. It needs to make itself relevant to the changing healthcare ecosystem and is well-positioned to do so but it could easily “miss the bus” on this if it carries on as is.
The future of the function is very much in our hands, Nathwani believes. “It depends on what we do next. In fact, I think we’re at a tipping point right now. We either prove our innovative value by adapting to and addressing the external changes happening in healthcare and our industry, or we will continue to remain a mainly support function. There’s a lot to do. If we can, for example, use Real World Evidence platforms to fundamentally change the way we carry out drug development, understand patients and diseases, and leverage these to bring through our biologic innovations faster, more safely and at a reduced cost, that to me will be a remarkable achievement.”
https://medicalaffairs.org/wp-content/uploads/2019/04/Rise.Medical.ELEVATE.png321845Medical Affairshttps://medicalaffairs.org/wp-content/uploads/2022/11/MAPS-Logo-R-NoTagLine.pngMedical Affairs2019-04-30 20:29:512023-11-13 10:34:52The Rise and Rise of Medical
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.